Share on StockTwits

Gilead Sciences (NASDAQ:GILD) EVP Norbert W. Bischofberger sold 90,000 shares of Gilead Sciences stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $80.90, for a total transaction of $7,281,000.00. Following the transaction, the executive vice president now directly owns 119,302 shares in the company, valued at approximately $9,651,532. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

GILD has been the subject of a number of recent research reports. Analysts at Jefferies Group reiterated a “buy” rating on shares of Gilead Sciences in a research note on Thursday, May 29th. Separately, analysts at Deutsche Bank raised their price target on shares of Gilead Sciences from $135.00 to $142.00 in a research note on Wednesday, May 28th. Finally, analysts at Zacks upgraded shares of Gilead Sciences from a “neutral” rating to an “outperform” rating in a research note on Friday, May 23rd. They now have a $99.00 price target on the stock. Two analysts have rated the stock with a hold rating and twenty-one have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $91.03.

Gilead Sciences (NASDAQ:GILD) traded down 0.40% during mid-day trading on Wednesday, hitting $79.47. 10,436,361 shares of the company’s stock traded hands. Gilead Sciences has a 1-year low of $46.70 and a 1-year high of $84.88. The stock has a 50-day moving average of $80.54 and a 200-day moving average of $77.17. The company has a market cap of $122.0 billion and a P/E ratio of 29.55. Gilead Sciences also was the target of a large drop in short interest in the month of May. As of May 30th, there was short interest totalling 94,135,575 shares, a drop of 4.2% from the May 15th total of 98,243,605 shares. Currently, 6.2% of the company’s shares are sold short. Based on an average daily trading volume, of 10,329,624 shares, the short-interest ratio is presently 9.1 days.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Tuesday, April 22nd. The company reported $1.48 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.85 by $0.63. The company had revenue of $5.00 billion for the quarter, compared to the consensus estimate of $3.80 billion. During the same quarter last year, the company posted $0.48 earnings per share. Gilead Sciences’s revenue was up 97.5% compared to the same quarter last year. On average, analysts predict that Gilead Sciences will post $6.28 earnings per share for the current fiscal year.

Gilead Sciences, Inc (NASDAQ:GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.